Prevention of Disuse Muscle Atrophy by Dietary Ingestion of 8-Prenylnaringenin in Denervated Mice

Rie Mukai, Hitomi Horikawa, Yutaka Fujikura, Tomoyuki Kawamura, Hisao Nemoto, Takeshi Nikawa, Junji Terao

1 Department of Food Science, Institute of Health Biosciences, University of Tokushima Graduate School, Tokushima, Japan, 2 Department of Pharmaceutical Chemistry, Institute of Health Biosciences, University of Tokushima Graduate School, Tokushima, Japan, 3 Department of Nutritional Physiology, Institute of Health Biosciences, University of Tokushima Graduate School, Tokushima, Japan

Abstract
Flavonoids have attracted considerable attention in relation to their effects upon health. 8-Prenylnaringenin (8-PN) is found in the common hop (Humulus lupulus) and assumed to be responsible for the health impact of beer consumption. We wanted to clarify the effects of prenylation on the physiological functions of dietary flavonoids by comparing the effects of 8-PN with that of intact naringenin in the prevention of disuse muscle atrophy using a model of denervation in mice. Consumption of 8-PN (but not naringenin) prevented loss of weight in the gastrocnemius muscle further supported by the lack of induction of the protein content of a key ubiquitin ligase involved in muscle atrophy, atrogin-1, and by the activation of Akt phosphorylation. 8-PN content in the gastrocnemius muscle was tenfold higher than that of naringenin. These results suggested that, compared with naringenin, 8-PN was effectively concentrated into skeletal muscle to exert its preventive effects upon disuse muscle atrophy. It is likely that prenylation generates novel functions for 8-PN by enhancing its accumulation into muscle tissue through dietary intake.

Introduction
Flavonoids are plant secondary metabolites derived from malonyl-CoA and p-coumaroyl-CoA. Flavonoids have attracted considerable attention in relation to their effects upon human health [1,2]. In prenyllavonoids, the C5 isoprenoid group is substituted in the diphenylpropane structure. Prenyllavonoids such as prenylchalcones, prenyllavones, prenyllavonol and prenyllavonanes are distributed mainly in the roots, leaves, and seeds [3,4]. In particular, prenyllavonanes occur mostly in Leguminosae, Moraceae and Asteraceae [3]. Recent studies have suggested that prenyllavonoids exert powerful biological functions. For example, the prenyllavonol icaritin was shown to prevent cell growth by inducing cell-cycle arrest in carcinoma cells [5]. Prenyllavonanes extracted from the roots of Sophora flavescens were found to possess antibacterial and anti-androgen activities [6]. Prenyllavones from Poria cocos polysaccharides and Mori Cortex Radices suppressed the production of nitric oxide in nerve cells [7,8]. Prenylation has been demonstrated to enhance the estrogenic activity of 8-PN in a rat serotonergic cell line [19]. These observations suggest the superiority of prenyllavonoids to non-prenyllavonoids within in vitro cell culture systems. However, little is known about the effect of prenylation on the physiological functions and bioavailability of dietary flavonoids in vivo. Recently, Sasaki et al. [11] discovered flavonoid prenyltransferase from the legume Sophora flavescens, and successfully undertook molecular cloning of this enzyme. That report urged us to explore a novel physiological function of prenyllavonoids because various prenyllavonoids seem to be readily prepared using this enzyme.

A prenylchalcone, (2) xanthohumol, is the principal flavonoid in the common hop (Humulus lupulus) [12]. In beer production, xanthohumol undergoes a ring-closing reaction, resulting in the formation of (3) isoxanthohumol [13]. This prenyllavonoid is further converted to (4) 8-prenylnaringenin (8-PN) by demethylation of the methoxy group attached to the diphenylpropane structure through the hepatic CYP450 reaction [14] and microflora metabolism in humans [15,16] (Figure 1). Therefore, humans may ingest 8-PN as a metabolic of isoxanthohumol as well as a hop ingredient in beer. Animal studies have revealed that a prenyllavonane, 8-PN, exerts beneficial effects against hot flushes [17] and bone loss [18]. Prenylation at the 8-position of naringenin was found to be responsible for the enhanced estrogenic activity of 8-PN in a rat serotonergic cell line [19]. These findings suggested that prenylation plays an important part in the physiological function of dietary flavonoids. Nevertheless, how prenylation enhances the physiological function of dietary flavonoids in the body is not known.

The aim of the present study was to compare the effect of 8-PN (prepared by chemical synthesis [20]) with that of non-prenylated naringenin (which is commonly found in grapefruit and sour...
oranges [21]) on disuse muscle atrophy using a denervation model in mice. This was done because estrogenic activity has been reported to be associated with muscle maintenance by activating Akt phosphorylation [22,23]. Denervation induces expression of atrogin-1 (a skeletal muscle-specific ubiquitin ligase) and mice deficient in atrogin-1 are resistant to muscle atrophy caused by denervation [24,25]. Phosphorylation of Akt has been suggested to suppress the expression of atrogin-1 by preventing activation of the transcription factor for atrogin-1: the Forkhead box-containing, O subfamily (FoxO) family of transcription factors [26,27,28].

We also examined the concentrations of 8-PN and naringenin in blood plasma and target muscle tissues to evaluate the effect of prenylation on the bioavailability and liability for transport to the target site in the prevention of muscle atrophy by dietary flavonoids. The results of the present study were expected to be helpful in estimation of the effects of brewery products on human health.

**Materials and Methods**

**Materials**

Naringenin was obtained from Tokyo Chemical Industry, Tokyo, Japan. 8-PN was synthesized by our research team [20]. Dried H. lupulus powder was obtained from Nippon Funmatsu Yakuhin (Osaka, Japan).

**Animal Experiments**

All experimental protocols were in accordance with the guidelines for the care and use of laboratory animals set by the Graduate School of the Institute of Health Biosciences, the University of Tokushima (Tokushima, Japan). The protocol was approved by the Committee on Animal Experiments of the University of Tokushima (permit number: 11013). All surgery was undertaken under anesthesia using sodium pentobarbital or ether. All efforts were made to minimize the suffering of the animals.

---

*(Figure 1. Conversion of xanthohumol to 8-prenylnaringenin (8-PN). doi:10.1371/journal.pone.0045048.g001)*
surgery was undertaken in the left leg of each mouse to obtain
in the gastrocnemius muscle (GM) (i.e., denervation). Sham
induce immobilization, and then disuse muscle atrophy provoked
water. The sciatic nerve in the right leg of each mouse was cut to
diet (AIN-93M; Oriental Yeast Company, Tokyo, Japan) and
light–dark cycle. They were allowed free access to a commercial
and water contents.

The GM was immediately used for the measurement of protein
until high-performance liquid chromatography (HPLC) analyses.

Experiment IV: Pharmacokinetics of 8-PN and Naringenin

Experiment III: Accumulation of 8-PN in the GM and

Experiment II: Preventive Effects of Continuous Intake of
8-PN and Naringenin on Disuse Muscle Atrophy

Eight-week-old male C57/BL6 mice (Japan SLC, Shizuoka,
Japan) were housed in a room maintained at 23±1°C on a 12-h
light–dark cycle. They were allowed free access to a commercial
diet (AIN-93M; Oriental Yeast Company, Tokyo, Japan) and
water. The sciatic nerve in the right leg of each mouse was cut to
reduce muscle atrophy provoked in the gastrocnemius muscle (GM) (i.e., denervation). Sham surgery was undertaken in the left leg of each mouse to obtain control muscle. The GM was collected and its weight measured 2, 4, and 6 days later.

Experiment II: Preventive Effects of Continuous Intake of
8-PN and Naringenin on Disuse Muscle Atrophy

8-PN or naringenin (5.6 mmol/kg diet) was mixed with AIN-
93M and given to mice. Cellulose content was reduced to adjust for the composition of other nutrients. Denervation was carried out on day 18. The GM was collected 4 or 6 days later. The level of atrophy in the GM was calculated to be the ratio of the weight of denervated muscle to the weight of control muscle in each mouse. Samples of the GM were stored at –80°C under N₂ gas until high-performance liquid chromatography (HPLC) analyses. The GM was immediately used for the measurement of protein and water contents.

Experiment III: Accumulation of 8-PN in the GM and

Plasma after Dietary Consumption

Experimental conditions (mice, feeding, denervation) until sample collection were identical to those described in experiment II. Blood collection and body reflux was performed before collection of the GM. Plasma was isolated from blood by centrifugation at 9,000 g for 10 min at 4°C. Samples of the GM and plasma were stored at –80°C under N₂ gas until HPLC analyses.

Experiment IV: Pharmacokinetics of 8-PN and Naringenin

Seven-week-old male C57/BL6 mice (Japan SLC) were housed in a room maintained at 23±1°C on a 12-h light–dark cycle. They were allowed free access to a commercial diet (AIN-93M) and water for 1 week. Before administration, they were deprived of food for 18 h, but had free access to water. 8-PN or naringenin dissolved in propylene glycol was administrated (30 mg/kg body weight [bw]) to mice by a gastric feeding tube. Blood was collected 0.25, 0.5, 1, 2, 4, 8, and 24 h after administration. Plasma was isolated by centrifugation at 9,000 xg for 10 min at 4°C and stored at –80°C under N₂ gas until use.

Experiment V: Preventive Effect of H. lupulus on Disuse
Muscle Atrophy

Dried H. lupulus powder was mixed (5% w/w) with AIN-93M and given to mice. Cellulose content was reduced to adjust for the composition of other nutrients. Denervation was carried out on day 14. The GM was collected 4 days later. The level of atrophy of the GM was calculated to be the ratio of the weight of denervated muscle to the weight of control muscle in each mouse.

Measurement of Water Content and Protein
Concentration in the GM

Water content in muscle was determined by measuring dry muscle weight [30]. About 50 mg of the wet mass of the GM was weighed, subjected to a drying heater at 70°C, and weighed every 60 min until a constant dry weight was obtained.

For the measurement of protein concentration, the GM was homogenized on ice in buffer containing 50 mM HEPES (pH 7.4), 4 mM ethylene glycol tetra-acetic acid (EGTA), 20 mM ethylene diamine tetra-acetic acid (EDTA), 0.1% Triton X-100, a protease inhibitor tablet (Complete; Roche Applied Science, Indianapolis, IN, USA) and a phosphatase inhibitor tablet (PhosSTOP; Roche Applied Science). Samples were incubated on ice for 1 h with shaking every 10 min. Samples were centrifuged at 20,000 xg for 20 min at 4°C. The supernatant was collected and protein concentration determined in triplicate using the Bradford method [31].

Western Blotting

The GM was homogenized on ice in buffer containing 50 mM Tris-HCl (pH 7.5), 150 mM NaCl, 5 mM EDTA, 1% Triton X-100, a protease inhibitor tablet (Complete) and a phosphatase inhibitor tablet (PhosSTOP). Samples were incubated on ice for 1 h with shaking every 10 min. Samples were centrifuged at 20,000 xg for 20 min at 4°C. Supernatants were collected as whole protein lysates. The protein concentration was determined in triplicate using the Bradford method [31]. Protein lysates were separated by 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). Proteins were transferred onto polyvinylidene difluoride membranes (GE Healthcare Piscataway, NJ, USA) followed by blocking of non-specific binding with a commercial blocking buffer (Blocking-One, Nacalai Tesque, Kyoto, Japan) for 1 h. Membranes were incubated with anti-atrogin-1 antibody (1:1,000 dilution; ECM Biosciences, Versailles, KY, USA) anti-pAKTser473 antibody (1:500; Cell Signaling Technology, Danvers, MA, USA), anti-pAKTser32 antibody (1:500; Cell Signaling Technology), anti-glyceraldehyde 3-phosphate dehydrogenase (GAPDH) antibody (1:3,000; Cell Signaling Technology), and ant-Akt antibody (1:1,000; Cell Signaling Technology) for 1 h at room temperature. After washing with Tris-buffered saline containing 0.05% Tween 20 (TBST), membranes were incubated with peroxidase-labeled secondary antibody for 1 h. After washing three times with TBST (for pAkt) or phosphate-buffered saline containing 0.05% Tween 20 (PBS) (for other proteins), immunocomplexes were visualized using a Chemiluminescence Detection Kit (ECL Prime, GE Healthcare BioScience) and analyzed by ImageJ software (National Institutes of Health, Bethesda, MD, USA).

Analyses of 8-PN and Naringenin in the GM

Each GM was homogenized with phosphate-buffered saline (PBS; 9-times volume of the weight of GM) using a Teflon Homogenizer (As One, Osaka, Japan) on ice. For analyses of total 8-PN or naringenin (conjugated metabolites plus aglycone) in the

Table 1. Protein and water content in the GM.

| Diet       | Condition | Protein content (mg/g GM) | Water content (% w/w) |
|------------|-----------|--------------------------|-----------------------|
| Control    | Sham      | 61.7±2.4                 | 76.2±0.29             |
| Denervation|           | 65.4±0.9                 | 75.8±0.52             |
| PN         | Sham      | 63.1±1.6                 | 76.3±0.52             |
| Denervation|           | 66.9±2.6                 | 77.3±0.37             |
| N          | Sham      | 59.1±2.1                 | 76.9±0.71             |
| Denervation|           | 62.9±1.6                 | 77.9±0.39             |

Data are the mean ± S.E. There was no significant difference among analyses by the Tukey multiple comparison test with one-way ANOVA (p<0.05).

DOI: 10.1371/journal.pone.0045048.t001
Figure 2. 8-PN can prevent disuse muscle atrophy by enhancing Akt phosphorylation. (a) Muscle atrophy induced by denervation. The weight of the GM was measured after denervation for the indicated period. Open bar: sham leg (left); closed bar: denervated leg (right). Data are the mean ± S.E (n = 4). Asterisks indicate significant differences between sham and the denervated leg (Student’s t-test, p<0.007). (b) Effect of dietary intake of 8-PN or naringenin on muscle atrophy. Mice consumed each flavonoid-mixed diet for 18 days, and denervation was then carried out. After 4 (black bar) or 6 (white bar) days, the level of atrophy in the GM was calculated as the ratio of the weight of denervated muscle to the weight of sham muscle in each mouse. Data are the mean ± S.E (n=4). C: control-diet group, 8-PN: 8-PN-containing diet group. Asterisks indicate significant
GM, muscle homogenates were mixed with 50 mM ascorbic acid (0.2-times volume of PBS) and 100 U/0.1 mL β-glucuronidase type H-1 solution (final concentration: 9 units/mg GM; Sigma–Aldrich, St Louis, MO, USA) and incubated for 2 h at 37°C. Hydrolysates were extracted three times with the same volume of ethyl acetate and evaporated using a Centrifugal Evaporator (CVE-100, Tokyo Rikakikai, Tokyo, Japan). Extracts were dissolved in 150 μL (for 8-PN) or 30 μL (for naringenin) of methanol containing 0.5% phosphoric acid. Twenty microliters of the sample were injected into the HPLC electrochemical detection system (700 mV; Coulochem III, ESA, Cambridge, MA, USA) equipped with a Cadenza 3-μm CD-C18 HPLC column (150×4.6 mm; Intakt, Hampshire, UK). Separation of compounds was carried out by gradient elution. Solvent A was 0.5% phosphoric acid, and solvent B was acetonitrile containing 0.5% phosphoric acid. For 8-PN detection, B was 65%. A was 0.5% phosphoric acid, and solvent B was methanol containing 0.5% phosphoric acid. For naringenin detection, the gradient program was: 0 min, 30% B; 0–15 min, linear gradient to 40% B; 13–35 min, linear gradient to 60% B; 35–36 min, linear gradient to 100% B; 36–39 min, 100% B; 39–40 min, linear gradient to 30% B; flow rate, 1 mL/min. For naringenin detection, the gradient program was: 0 min, 15% B; 0–10 min, linear gradient to 33% B; 15–25 min, linear gradient to 60% B; 25–26 min, linear gradient to 100% B; 26–30 min, 100% B; 30–31 min, linear gradient to 15% B; 31–35 min, 15% B; flow rate, 1 mL/min.

Cell Culture and Sample Preparation for Cellular Uptake

The mouse myoblast cell line C2C12 (American Type Culture Collection, Rockville, MD, USA) was maintained in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% fetal bovine serum, 100 U/mL penicillin, 100 μg/mL streptomycin, and 2 mM L-glutamine at 37°C in a humidified atmosphere containing 5% CO₂. Cells seeded on a 60-mm dish were cultured until confluent. Differentiation was initiated with 2% horse serum containing 5% CO₂. Cells seeded on a 60-mm dish were cultured and 2 mM L-glutamine at 37°C.

Sample Preparation for the Determination of Plasma Concentration

To analyze the concentration of metabolites and/or aglycone, plasma (10 μL) was incubated with 100 U of β-glucuronidase type H-1 (which possessed β-glucuronidase and sulphatase activity) in 0.1 M sodium acetate buffer, pH 5.0 (90 μL) and 50 mM ascorbic acid (20 μL) for 45 min. To measure the aglycone concentration, plasma without deconjugation treatment was applied to the experiment. Then, 100 pmol of pentamethyl quercetin (for 8-PN) or kaempferol (for naringenin) was added to samples as the internal standard. The liberated aglycone was extracted with ethyl acetate and evaporated using the Centrifugal Evaporator, and dissolved in 75 μL of methanol containing 0.5% phosphoric acid. A total of 25 μL of the sample was injected into the HPLC–UV detection system.

Calculation of ClogP Values

ClogP values of 8-PN and naringenin were calculated using ChemBioDraw Ultra ver11.0 (PerkinElmer, Waltham, MA, USA).

Statistical Analyses

Data are the mean ± SE. Data of protein content and water content in the GM, effect of dietary intake on 8-PN or naringenin on muscle atrophy and phosphorylation of Akt and atrogin-1 were analyzed by one-way ANOVA with the Tukey multiple comparison test (p<0.05). Data of the effect of naringenin on muscle atrophy and phosphorylation of Akt and atrogin-1 were analyzed by two-way ANOVA with the Tukey multiple comparison test (p<0.05). Data of the effect of denervation on muscle atrophy, effect of H. lupulus on muscle atrophy as well as pharmacokinetic parameters of 8-PN and naringenin were analyzed by the two-sided Student’s t-test (p<0.05).
8-Prenylnaringenin Prevents Disuse Muscle Atrophy

Figure 3. Accumulation of 8-PN in the GM. (a)–(e): HPLC chromatograms for quantitative analyses of 8-PN or naringenin in the GM. Chromatograms from mice fed an 8-PN-containing diet (a) and control diet (b). Chromatograms from mice fed a naringenin-containing diet (c) and control diet (d). (a) and (b) were obtained by the analytical condition for 8-PN. (c) and (d) were obtained by the analytical condition for naringenin. These analyses were undertaken by HPLC with electrochemical detection. (e) Contents of these flavonoids in the GM as determined by HPLC analysis. Data are the mean ± S.E (n = 4). Different letters indicate significant differences analyzed by the Tukey multiple comparison test with two-way ANOVA (p = 0.00043). doi:10.1371/journal.pone.0045048.g003

Accumulation of 8-PN in the GM

The contents of 8-PN and naringenin in the GM were determined by HPLC analyses with electrochemical detection employing deconjugation treatment using β-glucuronidase (which also had sulphatase activity) (Figures 3a–d). Peaks attributable to 8-PN and naringenin appeared in the chromatogram of the extract from the GM of mice fed diets containing 8-PN and naringenin, respectively (Figures 3a and c). The retention times of these peaks coincided with those for the standards of 8-PN and naringenin. No peaks appeared at the corresponding retention times in the chromatogram from mice fed the control diet (Figures 3b and d), indicating that both flavonoids could accumulate in GM tissue by oral intake of 8-PN and naringenin. Total amounts of flavonoids (including both aglycones and their conjugated metabolites) could be obtained by deconjugation of the extracts. The content of total 8-PN was 4.12 ± 0.56 nmol/g tissue (sham: without denervation) and 6.44 ± 1.65 nmol/g tissue (with denervation). The content of total naringenin was approximately tenfold lower than that of total 8-PN: 0.56 ± 0.04 nmol/g tissue (sham: without denervation) and 0.07 ± 0.02 nmol/g tissue (with denervation) (Figure 3e). We further determined the contents of total flavonoids and their aglycones in GM. To avoid blood contamination in the GM, we carried out a body reflux before GM collection (experiment III). The content of total 8-PN was 2.26 ± 0.33 nmol/g tissue (sham: without denervation) and 3.00 ± 0.30 nmol/g tissue (with denervation), and total naringenin was 0.26 ± 0.04 nmol/g tissue (sham: without denervation) and 0.23 ± 0.02 nmol/g tissue (with denervation) (Table 2). These results correlated with one of the experiment without a blood reflux under identical experimental conditions (experiment II). These data suggested that prenylation dramatically increased naringenin accumulation in skeletal muscle. The content of the aglycone in GM was 0.35 ± 0.09 nmol/g tissue (sham: without denervation) and 0.50 ± 0.06 nmol/g tissue (with denervation) (Table 2). 8-PN accumulated in muscle tissue mostly as its conjugated metabolites (although its aglycone also accumulated at a low level).

Cellular Uptake of 8-PN in Mouse C2C12 Myotubes

We calculated the logarithm of the n-octanol/water partition coefficient (i.e., ClogP) of 8-PN and naringenin as an index of their hydrophobicity. We measured their uptake in mouse C2C12 myotubes to understand the reasons for the enhanced accumulation by prenylation of naringenin. Prenylation increased the hydrophobicity of naringenin because the ClogP of 8-PN and naringenin were calculated to be 4.40 and 2.44, respectively. 8-PN was incorporated into cells and/or associated with cellular membranes at a much higher level than that observed in naringenin, and remained in cells at a constant level until 24 h of incubation (Figure 4). These results suggested that prenylation of naringenin accelerated cellular uptake and inhibited the excretion of naringenin from mouse C2C12 myotubes. The resulting higher accumulation in the cell and/or association with cell membranes could be correlated with an increase in hydrophobicity due to prenylation.

Table 2. Accumulation of 8-PN and naringenin in the GM and plasma after their dietary intake for 22 days.

| GM          | 8-PN          | Naringenin    |
|-------------|---------------|---------------|
|             | Sham          | Denervation   | Sham          | Denervation   |
| Total (nmol/g tissue, n = 7) | 2.26 ± 0.33<sup>a</sup> | 3.00 ± 0.30<sup>a</sup> | 0.26 ± 0.04<sup>b</sup> | 0.23 ± 0.02<sup>b</sup> |
| Aglycone (nmol/g tissue, n = 6) | 0.35 ± 0.09<sup>a</sup> | 0.50 ± 0.06<sup>a</sup> | Not determined | Not determined |

Plasma

|            | 8-PN          | Naringenin    |
|------------|---------------|---------------|
| Total (μM, n = 7) | 38.5 ± 2.72<sup>a</sup> | Not detected | ≤ 0.025 |
| Aglycone (μM, n = 7) | 0.06 ± 0.01<sup>a</sup> | Not detected | ≤ 0.025 |

Blood was collected from mice fed flavonoid (5.6 mmol flavonoid/kg diet) for 22 days, and then total body reflux was carried out. The GM was collected after the reflux. Plasma was prepared from the blood as described in the Materials and Methods section. Values of the total 8-PN and total naringenin indicate the sum of aglycone and conjugated metabolites obtained by the HPLC analysis with deconjugation treatment. Amount of flavonoids was determined by HPLC analyses as described in the Materials and Methods section. Data are the mean ± S.E. Different letters indicate significant differences upon analyses by the Tukey multiple comparison test with two-way ANOVA (p = 1.79 × 10<sup>−7</sup>). doi:10.1371/journal.pone.0045048.t002

diet, 0.57 ± 0.01; PN diet, 0.55 ± 0.02; naringenin diet, 0.58 ± 0.01; mean ± SE, n = 4). With respect to water and protein contents, there were no differences among all groups (Table 1). This finding suggested that GM content was affected by 8-PN-intake as well as denervation. These findings suggested that the prenyl group was essential for 8-PN to exert its preventive effects on loss in muscle weight.

The phosphorylation of residue ser-473 on Akt was measured to ascertain whether 8-PN affects the balance of synthesis and degradation of proteins in the inhibition of disuse muscle atrophy (Figure 2c). The GM 6 days after denervation was applied for western blotting. Total Akt expression was increased by denervation, and 8-PN intake showed no effect on the expression. Although Akt phosphorylation was lowered by denervation, 8-PN intake retained the phosphorylation status on Akt in denervated muscle similar to that seen with sham muscle. No differences were observed in GAPDH contents among all groups. We also detected atrogin-1 in the GM. Denervation increased the level of atrogin-1. Intake of 8-PN suppressed the atrogin-1 level in the denervated muscle, suggesting that 8-PN intake delayed the development of disuse muscle atrophy due to suppression of protein degradation.
Blood Circulation of 8-PN in Mice

We investigated the plasma concentration and pharmacokinetics of 8-PN and naringenin as an index of their bioavailability by stomach intubation of these flavonoids in mice. Plasma concentrations of total 8-PN and total naringenin were obtained by HPLC analyses with UV detection by deconjugation treatment. In contrast with muscular accumulation, the values of the maximum concentration achieved after dosing (C_{max}) and area under the curve (AUC) for 8-PN were significantly lower than those for naringenin (Figure 5 and Table 3). This finding suggested that the bioavailability of 8-PN was lower than that of naringenin for a single dose. Nevertheless, the plasma concentration of 8-PN at 24 h (2.6 \pm 0.28 \mu M) was higher than that seen with naringenin (0.46 \pm 0.28 \mu M) (Table 3). Moreover, the denervation model in mice showed that 8-PN was present in plasma at 38.5 \pm 2.7 \mu M mostly as its conjugated metabolites after mice were continuously fed an 8-PN-containing diet for 22 days, whereas naringenin was not detected in plasma under identical conditions (Table 2). This result suggested that the plasma concentration of 8-PN was increased gradually during continuous consumption, and was different to that seen with non-prenylated naringenin.

Preventive Effects of *H. lupulus* Powder on Disuse Muscle Atrophy

We used *H. lupulus* powder as a source of prenylated flavonoids (including 8-PN). A mixed diet of *H. lupulus* powder (5% (w/w) in the diet) was given to mice for 14 days before denervation. Dietary intake of *H. lupulus* powder significantly suppressed the loss in muscle weight (Figure 6).

### Discussion

Disuse muscle atrophy is an urgent public healthcare issue in aging societies because it is closely associated with the bedridden state [33]. However, medications for the relief of this condition are not available. Our previous study [1] revealed that periodic injection of the flavonol-type flavonoid quercetin into the GM was effective for prevention of the loss of muscle weight in mice that underwent tail suspension (which was used as a model of disuse muscle atrophy). Therefore, skeletal muscle is one of the target tissues of flavonoids for exerting their pharmacological functions. We first demonstrated that a prenylflavonoid prevented the loss of function of the GM in mice that underwent sciatic denervation (which is an alternative model of disuse muscle atrophy) (Figure 2). The prenylflavonoid 8-PN was administered orally to mice by mixing with the diet for 18 days before denervation. Hence, 8-PN was assumed to prevent disuse muscle atrophy after intestinal absorption and transport into the target muscle tissue. It can be deduced that prenylation increases the bioavailability of a continuously ingested flavonoid and promotes its accumulation in muscle because the plasma concentration of total 8-PN and its metabolites was increased gradually during continuous consumption.
We selected 8-PN for evaluation of the structural significance of prenylation in dietary flavonoids for exertion of their physiological functions. Binding of the prenyl group to the molecule should accelerate intestinal absorption by passive diffusion because such binding increases lipophilicity and allows the molecule to have a higher affinity to cellular membranes [42]. High accumulation of 8-PN in muscle tissue and the appearance of preventive effects may be derived from its high bioavailability based on effective absorption in the intestine. However, the time-courses of the plasma concentrations of 8-PN and naringenin in a single dose (Figure 5) and their values of C_{max} and AUC shown in Table 3 indicated that the prenylation of flavonoids lowered their effectiveness with regard to intestinal absorption and blood circulation. Pang et al. [43] reported that a prenylated chalcone exhibits little efflux into the basolateral side when incorporated into Caco-2 cells (a cellular model of intestinal absorption). It is therefore likely that prenylation suppresses the intestinal absorption of flavonoids by interfering with efflux into the portal vein. In contrast, the plasma concentration of total 8-PN 24 h after administration was significantly higher than that seen with naringenin (Table 3), indicating that prenylation reduces the rate of elimination into urine. This may be why 8-PN was present in plasma at a considerable level after its ingestion for 22 days (Table 2). Our study on uptake using cultured mouse C2C12 myotubes (Figure 4) strongly suggested that prenylation significantly enhanced the accumulation of flavonoids within cells and/or their association to cellular membranes in mouse C2C12 myotubes because it increased passive transport into cells and interaction with cellular membranes owing to increased lipophilicity. Therefore, prenylation seems to be an effective tool to improve the physiological functions of dietary flavonoids by increasing the concentration to target tissues through a reduction in the rate of elimination from the circulation and higher uptake into cells.

Results from studies on denervated mice demonstrated that 8-PN suppressed atrogin-1 content in denervated muscle compared with control-diet mice (Figure 2c). 8-PN is known to be a powerful phytoestrogen [44,45,46]. Some studies suggest that estrogenic status affects recovery from disuse muscle atrophy by accelerating the Akt signaling pathway [22,23]. That is, estrogen deficiency inhibits the reproduction of muscle, and estradiol supplementation accelerates the regeneration of skeletal muscles. Our results clearly indicated that 8-PN intake accelerated Akt phosphorylation (Figure 2c). Taken together, the mechanism for 8-PN-dependent prevention of muscle atrophy may be related to its estrogenic activity, which can promote post-natal growth and delay the degradation of skeletal muscles. Insulin-like growth factor-1 (IGF1)/phosphatidylinositol 3-kinase (PI3K)/Akt pathway-mediated phosphorylation of FoxOs by FoxOs by elevating the phosphorylated Akt level. 8-PN may also induce protein synthesis because hypertrophy in skeletal muscle was also shown to be activated by the IGF1/PI3K/Akt pathway [47]. Further study is required to clarify exact mechanism for the preventive effects of 8-PN on disused muscle atrophy.

8-PN is a demethylated metabolite of isoaxanthohumol through the CYP450 reaction in the liver [14]. This prenylated flavonoid can also be produced from isoaxanthohumol by the action of microflora in the digestive tract [13,16] Isoxanthohumol is produced from xanthohumol via a ring-closing reaction during brewing [12,13]. Therefore, xanthohumol and isoaxanthohumol present in H. lupulus and beer can act as pro-8-PN. Stevens et al.
showed levels of isoaxanthohumol and 8-PN in beer to be 40–3,440 µg/L and 1–240 µg/L, respectively [12]. It has been shown that, in healthy post-menopausal Caucasian women, nearly 25% were moderate producers and 15% were strong producers of 8-PN based on urinary excretion through microbial conversion capacities [30]. A clinical study demonstrated that orally administered 8-PN was absorbed rapidly at a very limited level and was associated with decreased concentrations of luteinizing hormone in postmenopausal women [36]. Therefore, diets or supplements containing 8-PN (or an 8-PN precursor) could be beneficial for human health. H. lupulus is known to contain isoaxanthohumol and 8-PN at 0.1–1.0% [12]. The results regarding intake of H. lupulus (Figure 6) could suggest the beneficial effects of H. lupulus on the prevention of disuse muscle atrophy. Bolca et al. found that 8-PN could accumulate in human breast tissue if 8-PN producers were prevented from disuse muscle atrophy. Bolca et al. found that 8-PN containing 8-PN (or an 8-PN precursor) could be beneficial for people.

References

1. Mukai R, Nakao R, Yamamoto H, Nukawa T, Takeno E, et al. (2010) Quercetin Prevents Unloading-Driven Disuse Muscle Atrophy by Attenuating the Induction of Ubiquitin Ligases in Tail-Suspension Mice. J Nat Prod 73: 1708–1710.
2. Teraso J (2009) Dietary flavonoids as antioxidants. Forum Nutr 61: 87–94.
3. Barron D, Ibrahim RK (1996) Isoflavonoid flavonoids – A survey. Phytochemistry 43: 921–982.
4. Iotta B, Vitali A, Menendez P, Miotti D, Belle Monache G (2005) Prenylated flavonoids. Pharmacology and biotechnology. Current Medicinal Chemistry 12: 713–739.
5. Huang X, Zhu D, Lou Y (2007) A novel anticancer agent, icaritin, induced cell growth inhibition, G1 arrest and mitochondrial transmembrane potential drop in human prostate carcinoma PC-3 cells. Eur J Pharmacol 564: 26–36.
6. Kuroyanagi M, Nakanta T, Hirayama Y, Hayashi T (1999) Antibacterial and antiangiogenesis activities of Sophora flavescens. J Nat Prod 62: 1959–1959.
7. Lee MH, Kim JY, Ryu JH (2005) Prenylflavonoids from Postarea coriifolia inhibit nitric oxide synthase expression through the inhibition of I-kappaB-alpha degradation in activated microglial cells. Biol Pharm Bull 28: 2255–2257.
8. Lee HJ, Lyu da H, Koo U, Nam KW, Hong SS, et al. (2012) Protection of prenylated flavonoids from Mori Cortex Radicis (Moraceae) against nitric oxide-induced cell death in neuroblastoma SH-SY5Y cells. Archives of Pharmacal Research 35: 163–170.
9. Kretzschmar G, Zierau O, Weber J, Tischer S, Metz P, et al. (2010) Prenylation isoxanthohumol and related prenylflavonoids in hops and beer by liquid chromatography tandem mass spectrometry. Journal of Chromatography A 1232: 97–107.
10. Stevens JF, Taylor AW, Deimier ML (1999) Quantitative analysis of xanthohumol and related prenylflavonoids in hops and beer by liquid chromatography-tandem mass spectrometry. Journal of Chromatography A 832: 97–107.
11. Stevens JF, Taylor AW, Clawson JE, Deimier ML (1999) Fate of xanthohumol and related prenylflavonoids from hops to beer. J Agric Food Chem 47: 2421–2430.
12. Guo J, Nikolic D, Chadwick LR, Pauli GF, van Breemen RB (2006) Prenylation of xanthohumol and related prenylflavonoids from hops (Humulus lupulus L.) Drug Metab Dispos 34: 1152–1159.
13. Bolca S, Possemiers S, Maervoet V, Huybrechts I, Heyerick A, et al. (2007) Microbial and dietary factors associated with the 8-prenylnaringenin producer phenotype: a dietary intervention trial with fifty healthy post-menopausal Caucasian women. British Journal of Nutrition 98: 950–959.
14. Possemiers S, Bolca S, Grootaert C, Heyerick A, Decroos K, et al. (2006) The prenylflavonoid isoaxanthohumol from hops (Humulus lupulus L.) is acted upon by the prenyltransferase from hops in vitro and in the human intestine. J Nutr 136: 1862–1867.
15. Bowe J, Li XF, Kinsey-Jones J, Heyerick A, Brain S, et al. (2006) The hop prenylation, 8-prenylnaringenin, reverses the ovariole-induced rise in skin temperature in an animal model of menopausal hot flushes. J Endocrinol 191: 395–405.
16. Humpel M, Isaksson P, Schafer O, Kauffmann U, Ciana P, et al. (2005) Tissue specificity of 8-prenylnaringenin: protection from ovariole-induced bone loss with minimal trophic effects on the uterus. J Steroid Biochem Mol Biol 97: 299–305.
17. Amer DA, Kretzschmar G, Muller N, Stanke N, Lindemann D, et al. (2010) Activation of transgenic estrogen receptor-beta by selected phytoestrogens in a stably transduced rat serotonergic cell line. J Steroid Biochem Mol Biol 120: 208–217.
18. Kawamura T, Hayashi M, Mukai R, Teraso J, Nemoto H (2012) An Efficient Method for ClpP-Preylation of Flavanoids and Flavonones. Synthesis 44: 1308–1314.
19. Tomasz-Barberen FA, Cliffond MN (2000) Flavanones, chalcones and dihydrochalcones - nature, occurrence and dietary burden. Journal of the Science of Food and Agriculture 80: 1073–1080.
20. McClung JM, Davis JM, Wilson MA, Goldsmith EC, Carson JA (2006) Estrogen status and skeletal muscle recovery from disuse atrophy. J Appl Physiol 100: 2012–2023.
21. Brown M, Foley A, Ferreria JA (2005) Ovariectomy, hindlimb unweighting, and recovery effects on skeletal muscle in adult rats. Aviat Space Environ Med 76: 1012–1018.
22. Gomes MD, Lecker SH, Jagoe RT, Navon A, Goldberg AL (2001) Atrogin-1, a muscle-specific F-box protein highly expressed during muscle atrophy. Proceedings of the National Academy of Sciences of the United States of America 98: 14440–14445.
23. Bodine SC, Laters E, Baumhueter S, Lai VK, Nunez L, et al. (2001) Identification of ubiquitin ligases required for skeletal muscle atrophy. Science 294: 1704–1708.
24. Sandri M, Sandri C, Gilbert A, Skurk C, Calabria E, et al. (2004) Foxo transcription factors induce the atrophy-related ubiquitin ligase atrogin-1 and cause skeletal muscle atrophy. Cell 117: 399–412.
25. Sent SM, Dodd SL, McClung JM, Judge AR (2008) Hep70 overexpression inhibits NF-kappaB and Foxo3a transcriptional activities and prevents skeletal muscle atrophy. FASEB Journal 22: 3086–3085.
26. Sinti TN, Donjon D, Clarke BA, Panaro F, Timofrakya Y, et al. (2004) The IGF-1/PI3K/Akt pathway prevents expression of muscle atrophy-induced ubiquitin ligases by inhibiting FOXO transcription factors. Molecular and Cellular Biology 24: 1395–403.
27. Bodine SC, Sinti TN, Gonzalez M, Klinc WO, Stover GL, et al. (2001) Akt/mTOR pathway is a crucial regulator of skeletal muscle hypertrophy and can prevent muscle atrophy in vivo. Nat Cell Biol 3: 1014–1019.
28. McClung JM, Davis JM, Wilson MA, Goldsmith EC, Carson JA (2006) Estrogen status and skeletal muscle recovery from disuse atrophy. J Appl Physiol 100: 2012–2023.
29. Brown M, Foley A, Ferreria JA (2005) Ovariectomy, hindlimb unweighting, and recovery effects on skeletal muscle in adult rats. Aviat Space Environ Med 76: 1012–1018.
30. Gomes MD, Lecker SH, Jagoe RT, Navon A, Goldberg AL (2001) Atrogin-1, a muscle-specific F-box protein highly expressed during muscle atrophy. Proceedings of the National Academy of Sciences of the United States of America 98: 14440–14445.
31. Bodine SC, Laters E, Baumhueter S, Lai VK, Nunez L, et al. (2001) Identification of ubiquitin ligases required for skeletal muscle atrophy. Science 294: 1704–1708.
32. Sandri M, Sandri C, Gilbert A, Skurk C, Calabria E, et al. (2004) Foxo transcription factors induce the atrophy-related ubiquitin ligase atrogin-1 and cause skeletal muscle atrophy. Cell 117: 399–412.
33. Sent SM, Dodd SL, McClung JM, Judge AR (2008) Hep70 overexpression inhibits NF-kappaB and Foxo3a transcriptional activities and prevents skeletal muscle atrophy. FASEB Journal 22: 3086–3085.
34. Sinti TN, Donjon D, Clarke BA, Panaro F, Timofrakya Y, et al. (2004) The IGF-1/PI3K/Akt pathway prevents expression of muscle atrophy-induced ubiquitin ligases by inhibiting FOXO transcription factors. Molecular and Cellular Biology 24: 1395–403.
35. Bodine SC, Sinti TN, Gonzalez M, Klinc WO, Stover GL, et al. (2001) Akt/mTOR pathway is a crucial regulator of skeletal muscle hypertrophy and can prevent muscle atrophy in vivo. Nat Cell Biol 3: 1014–1019.
36. McClung JM, Davis JM, Wilson MA, Goldsmith EC, Carson JA (2006) Estrogen status and skeletal muscle recovery from disuse atrophy. J Appl Physiol 100: 2012–2023.
34. Fang T, Wang Y, Ma Y, Su W, Bai Y, et al. (2006) A rapid LC/MS/MS quantitation assay for naringin and its two metabolites in rats plasma. J Pharm Biomed Anal 40: 454–459.

35. Hsiu SL, Huang TY, Hou YC, Chin DH, Chao PD (2002) Comparison of metabolic pharmacokinetics of naringin and naringenin in rabbits. Life Sci 70: 1481–1489.

36. Rad M, Humpel M, Schaefer O, Schoemaker RC, Schleuning WD, et al. (2006) Pharmacokinetics and systemic endocrine effects of the phyto-oestrogen 8-prenylnaringenin after single oral doses to postmenopausal women. Br J Clin Pharmacol 62: 288–296.

37. Williamson G, Barron D, Shimoi K, Terao J (2005) In vitro biological properties of flavonoid conjugates found in vivo. Free Radical Research 39: 457–469.

38. Bieger J, Cermak R, Blank R, de Boer VC, Hollman PC, et al. (2008) Tissue distribution of quercetin in pigs after long-term dietary supplementation. J Nutr 138: 1417–1420.

39. Shimoi K, Nakayama T (2005) Glucuronidase deconjugation in inflammation. Methods Enzymol 400: 263–272.

40. Terao J, Murota K, Kawai Y (2011) Conjugated quercetin glucuronides as bioactive metabolites and precursors of aglycone in vivo. Food Funct 2: 11–17.

41. Menendez C, Durnas M, Galindo P, Gonzalez-Manzano S, Jimenez R, et al. (2011) Vascular deconjugation of quercetin glucuronide: the flavonoid paradox revealed? Mol Nutr Food Res 55: 1780–1790.

42. Barron D, Ballard C, Possety F, Ravaud P, Desfougeres A (1996) Prenyl flavonoids and membrane permeability. Acta Botanica Gallica 143: 509–520.

43. Pang Y, Nikolic D, Zhu D, Chadwick LR, Pauli GF, et al. (2007) Binding of the hop (Humulus lupulus L.) chalcone xanthohumol to cytosolic proteins in Caco-2 intestinal epithelial cells. Mol Nutr Food Res 51: 872–879.

44. Milligan SR, Kalita JC, Pocock V, Van de Kauter V, Stevens JF, et al. (2000) The endocrine activities of 8-prenylnaringenin and related hop (Humulus lupulus L.) flavonoids. Journal of Clinical Endocrinology & Metabolism 85: 4912–4915.

45. Milligan SR, Kalita JC, Heyrick A, Roug H, De Cooman L, et al. (1999) Identification of a potent phytoestrogen in hops (Humulus lupulus L.) and beer. Journal of Clinical Endocrinology & Metabolism 84: 2249–2252.

46. Coldham NG, Sauer MJ (2001) Identification, quantitation and biological activity of phytoestrogens in a dietary supplement for breast enhancement. Food and Chemical Toxicology 39: 1211–1224.

47. Ronnel C, Bodine SC, Clarke BA, Rossman R, Nunez L, et al. (2001) Mediation of IGF-1-induced skeletal myotube hypertrophy by PI(3)K/Akt/mTOR and PI(3)K/Akt/GSK3 pathways. Nat Cell Biol 3: 1009–1013.

48. Bolca S, Li JJ, Nikolic D, Roche N, Blondeel P, et al. (2010) Disposition of hop prenylflavonoids in human breast tissue. Mol Nutr Food Res 54 Suppl 2: S284–294.